Current and emerging therapies for coeliac disease

Laura Kivelä, Alberto Caminero, Daniel A. Leffler, Maria Ines Pinto-Sanchez, Jason A. Tye-Din, Katri Lindfors

Research output: Contribution to journalReview Articlepeer-review

4 Citations (Scopus)
23 Downloads (Pure)

Abstract

Coeliac disease is a common enteropathy that occurs in genetically susceptible individuals in response to the ingestion of gluten proteins present in wheat, rye and barley. Currently, the only available treatment for the condition is a strict, life-long gluten-free diet that, despite being safe and often effective, is associated with several challenges. Due to the high cost, particularly restrictive nature and perception of decreased quality of life associated with the diet, some patients are continuously exposed to gluten, which prevents an adequate disease control. Moreover, a subgroup of patients does not respond to the diet adequately, and healing of the small-bowel mucosa can be incomplete. Thus, there is a need for alternative treatment forms. The increasingly understood pathogenetic process of coeliac disease has enabled the identification of various targets for future therapies. Multiple investigational therapies ranging from tolerogenic to immunological approaches are in the pipeline, and several drug candidates have entered phase II/III clinical trials. This Review gives a broad overview of the different investigative treatment modalities for coeliac disease and summarizes the latest advances in this field.

Original languageEnglish
Pages (from-to)181-195
Number of pages15
JournalNATURE REVIEWS GASTROENTEROLOGY AND HEPATOLOGY
Volume18
Issue number3
Early online date20 Nov 2020
DOIs
Publication statusPublished - Mar 2021
Publication typeA2 Review article in a scientific journal

Keywords

  • Celiac Disease/etiology
  • Diet, Gluten-Free
  • Humans

Publication forum classification

  • Publication forum level 2

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Fingerprint

Dive into the research topics of 'Current and emerging therapies for coeliac disease'. Together they form a unique fingerprint.

Cite this